This is consistent with findings in COVID-19 patients, in which NSAID treatment suppressed neutralizing cytokines and immune responses such as IL-6, MIP-1, and GM-CSF without affecting the infiltration of innate and adaptive immune cells into the lung (48). The gene discussed is CSF2; the disease is COVID-19.